Sinopharm Covid-19 booster weaker against Omicron - study | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Monday
December 04, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
MONDAY, DECEMBER 04, 2023
Sinopharm Covid-19 booster weaker against Omicron - study

Coronavirus chronicle

Reuters
20 December, 2021, 02:15 pm
Last modified: 20 December, 2021, 02:45 pm

Related News

  • DGHS urges to wear masks, take booster dose amid fresh Covid outbreak in China, India
  • Some Omicron sub-variants escaping antibodies from Sinopharm shot
  • Weeklong booster dose campaign targeting to vaccinate 1.42cr kicks off
  • Prior Covid offers less protection vs Omicron; mRNA booster shot efficacy declines within months
  • Covid booster efficacy wanes significantly by fourth month: US study

Sinopharm Covid-19 booster weaker against Omicron - study

However, the study authors cautioned the results were not equal to how well a Sinopharm booster could shield recipients from diseases caused by Omicron, as neutralisation is only part of the human immune response

Reuters
20 December, 2021, 02:15 pm
Last modified: 20 December, 2021, 02:45 pm
Photo: Reuters
Photo: Reuters

A Covid-19 booster shot produced by China's Sinopharm had "significantly lower" neutralising activity against the Omicron variant, Chinese researchers said in a paper, although they added the vaccine's efficacy against Omicron remained unclear.

The study - conducted by researchers from Shanghai Jiao Tong University and a Shanghai-based lab specializing in respiratory infectious diseases - compared the activity of Sinopharm's booster vaccine against an older coronavirus strain from Wuhan.

The neutralising antibody activity of a Sinopharm BBIBP-CorV booster against Omicron showed a 20.1-fold reduction, compared with its activity against a Wuhan strain, according to the paper published on Saturday.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Sinopharm did not immediately respond to a request for comment.

Sinopharm's BBIBP-CorV vaccine and Sinovac Biotech's CoronaVac are the two most used vaccines in China and are the leading Covid-19 vaccines exported by the country. Sinopharm also has a second vaccine in use in China.

The study analysed samples from 292 healthcare workers who received a third dose, or booster shot, about eight to nine months after their second dose. After a further four weeks, serum samples from 78.1% participants retained neutralising activity against Omicron, researchers said in a paper that has not been peer reviewed.

However, the study authors cautioned the results were not equal to how well a Sinopharm booster could shield recipients from diseases caused by Omicron, as neutralisation is only part of the human immune response.

The testing against the earlier Wuhan strain showed that about eight to nine months after the second BBIBP-CorV shot, the neutralizing activity "could hardly be detected", while the booster lifted the response significantly, according to the paper.

Top News / World+Biz

Sinopharm / booster

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • For the first time, Bangladesh seeks foreign loans to support Rohingyas
    For the first time, Bangladesh seeks foreign loans to support Rohingyas
  • Treasury bill interest rate tops 11%
    Treasury bill interest rate tops 11%
  • File Photo of Prime Minister Sheikh Hasina
    PM to hold meeting with leaders of 14-party alliance tomorrow

MOST VIEWED

  • Representative image
    5.5 magnitude earthquake jolts Dhaka, parts of country
  • Cox's Bazar Express started its first journey from Cox's Bazar to Dhaka at 12:40pm on Friday (1 December). Photo: Nupa Alam
    Man crushed by Cox's Bazar Express on debut journey
  • Representative image
    BCS admin cadres' organisation forays into luxury hotel business
  • Will Bangladeshi garment exporters be able to meet EU's upcoming standards?
    Will Bangladeshi garment exporters be able to meet EU's upcoming standards?
  • 5 renewable power projects on cards to counter global fuel price surge
    5 renewable power projects on cards to counter global fuel price surge
  • Collage of the Android Earthquake Alerts System screenshots posted on the social media on Saturday, 2 December 2023
    Here’s how your Android phone alerts you of an earthquake

Related News

  • DGHS urges to wear masks, take booster dose amid fresh Covid outbreak in China, India
  • Some Omicron sub-variants escaping antibodies from Sinopharm shot
  • Weeklong booster dose campaign targeting to vaccinate 1.42cr kicks off
  • Prior Covid offers less protection vs Omicron; mRNA booster shot efficacy declines within months
  • Covid booster efficacy wanes significantly by fourth month: US study

Features

Designed for utility, the D90 is a giant in comparison to other MG models and misses out on design elements which gives the other models their sporty stance. Photo: Akif Hamid

Maxus D90: Spacious, capable and practical

11h | Wheels
Maria Callas: Remembering the soprano diva on her century

Maria Callas: Remembering the soprano diva on her century

10h | Features
Photo: Touseful Islam

Last sip of coffee with cats: Bidding adieu to Capawcino

12h | Features
Jannatul Ferdous Ivy has written 11 books so far with the latest, a series of poems, being published this year. Photo: Noor-A-Alam

Jannatul Ferdous Ivy: Overcoming tragedy, excelling in life

20h | Panorama

More Videos from TBS

Euro champion Italy in 'Group of Death' with Spain and Croatia

Euro champion Italy in 'Group of Death' with Spain and Croatia

7h | TBS SPORTS
Will Israel kill expatriate Hamas leaders after the war?

Will Israel kill expatriate Hamas leaders after the war?

6h | TBS World
Mahiya Mahi, Dolly Sayantani and Hero Alam's candidacy canceled!

Mahiya Mahi, Dolly Sayantani and Hero Alam's candidacy canceled!

10h | TBS Stories
Doctors of bike engines

Doctors of bike engines

8h | TBS Stories
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]